Clinical Trial Update: Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating camrelizumab plus apatinib and temozolomide as first-line therapy for advanced acral melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Melanoma | Phase 2 | Status: UNKNOWN